Mr. Aras Azadian reports

AVICANNA ANNOUNCES CHANGE IN CFO

Nick Hilborn, CPA, CA, vice-president of finance, has been appointed interim chief financial officer of Avicanna Inc., following the transition of Phillip Cardella, CPA, CA, to consultant, effective Monday, Sept. 15, 2025.

"We thank Phil for his contributions to the company during our most transformational years and wish him well as he takes on a leadership role with his family's businesses," stated Aras Azadian, chief executive officer. Mr. Azadian further stated: "Nick has held roles of progressively increasing responsibility since he joined us in 2024 and is familiar with the company, the culture and its people. We are excited to have Nick assume the role of interim chief financial officer."

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including research and development and clinical development, leading to the commercialization of more than 30 proprietary, evidence-based finished products and supporting four commercial-stage business pillars:

• Medical cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products, including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
• Medical cannabis care platform (MyMedi): MyMedi is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. MyMedi is operated by Northern Green Canada Inc., and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi also provides specialty services to distinct patient groups such as veterans, and collaborates with public and private payers for adjudication and reimbursement. MyMedi provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain and various neurological disorders.
• Active pharmaceutical ingredients (Aureus Santa Marta): The company's majority-owned subsidiary Santa Marta Golden Hemp is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the company's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. SMGH also forms part of the company's supply chain, and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally.

We seek Safe Harbor.